The US KOL favors a domain-driven, MDA-based approach, preferring IL-17 inhibitors over formulary-driven adalimumab biosimilars and using dual therapy with GLP-1 agonists. The KOL views bimekizumab as best in class, favors guselkumab over risankizumab for its structural and axial data, and notes safety concerns limiting Rinvoq. The interview closes with emerging options, including sonelokimab as a Bimzelx rival and deucravacitinib's lupus halo effect, while spine disease remains undertreated. 

This interview was conducted on March 12, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.